An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Du CaiWei WangMin-Er ZhongDejun FanXuanhui LiuCheng-Hang LiZe-Ping HuangQiqi ZhuMin-Yi LvChuling HuXin DuanXiao-Jian WuFeng GaoPublished in: Cancer medicine (2023)
We proposed an ISE signature for robustly predicting the recurrence of stage II/III CRC and help treatment decision by identifying patients who will not benefit from current standard treatment.